Jane Street Group, LLC Igm Biosciences, Inc. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 24,135 shares of IGMS stock, worth $214,560. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,135

Previous 13,743 75.62%

Holding current value

$214,560

Previous $94,000 324.47%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.28 - $17.68 $65,261 - $183,730	10,392 Added 75.62%	24,135 $399,000
Q2 2024 Aug 14, 2024	SELL	$6.51 - $11.47 $113,124 - $199,314	-17,377 Reduced 55.84%	13,743 $94,000
Q1 2024 May 15, 2024	SELL	$8.68 - $17.36 $39,190 - $78,380	-4,515 Reduced 12.67%	31,120 $300,000
Q4 2023 Feb 14, 2024	BUY	$3.94 - $8.79 $140,401 - $313,231	35,635 New	35,635 $296,000
Q1 2023 May 15, 2023	BUY	$13.74 - $25.76 $187,276 - $351,108	13,630 New	13,630 $187,000
Q2 2022 Aug 16, 2022	BUY	$13.27 - $25.5 $266,859 - $512,805	20,110 New	20,110 $363,000
Q4 2021 Feb 15, 2022	SELL	$27.59 - $66.39 $598,923 - $1.44 Million	-21,708 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$65.76 - $90.65 $965,554 - $1.33 Million	14,683 Added 209.01%	21,708 $1.43 Million
Q1 2021 May 18, 2021	BUY	$71.56 - $121.23 $231,425 - $392,057	3,234 Added 85.31%	7,025 $539,000
Q3 2020 Nov 17, 2020	SELL	$43.0 - $84.01 $109,005 - $212,965	-2,535 Reduced 40.07%	3,791 $280,000
Q2 2020 Aug 17, 2020	BUY	$51.3 - $75.21 $324,523 - $475,778	6,326 New	6,326 $462,000

Others Institutions Holding IGMS

# of Institutions

Shares Held

20.7M

Call Options Held

68K

Put Options Held

52.2K

View Full List

About IGM Biosciences, Inc.

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $258M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

More about IGMS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Igm Biosciences, Inc. Transaction History